Search
Barinthus Biotherapeutics PLC
BRNSAdd to Watchlist
0.558USD
+0.007+1.29%
Close 07-31 16:00（ET）Quotes delayed by 15 min
22.79MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Barinthus Biotherapeutics PLC is 8.00, ranking 171 out of 385 in the Biotechnology & Medical Research industry. The average price target is 5.50, with a high of 7.00 and a low of 4.00.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
5.500
Target Price
+858.69%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Barinthus Biotherapeutics PLC
BRNS
2
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Barinthus Biotherapeutics PLC's price target?
Analysts forecast that Barinthus Biotherapeutics PLC's price target is USD 5.50, with the highest forecast at USD 7.00 and the lowest forecast at USD 4.00.
How have Barinthus Biotherapeutics PLCBRNS's recent earnings per share performed?
The market expectation was USD -0.14, while Barinthus Biotherapeutics PLCBRNS's earnings per share (EPS) for the previous quarter was USD -0.27. EPS for the next quarter is expected at USD -0.28.
What is the analyst rating for Barinthus Biotherapeutics PLC?
Based on the ratings of Barinthus Biotherapeutics PLC's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.